Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.'The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.'Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 19 September 2026
2019-08-07 08:32:00 Wednesday ET
Our fintech finbuzz analytic report shines fresh light on the current global economic outlook. As of Summer-Fall 2019, the current analytic report focuses o
2025-09-14 14:23:00 Sunday ET
Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2023-06-07 10:27:00 Wednesday ET
Anat Admati and Martin Hellwig raise broad critical issues about bank capital regulation and asset market stabilization. Anat Admati and Martin Hellwig (
2017-08-25 13:36:00 Friday ET
The U.S. Treasury's June 2017 grand proposal for financial deregulation aims to remove several aspects of the Dodd-Frank Act 2010 such as annual macro s
2019-02-01 15:35:00 Friday ET
Our proprietary alpha investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implem
2020-05-14 12:35:00 Thursday ET
Disruptive innovators can better compete against luck by figuring out why customers hire products and services to accomplish jobs. Clayton Christensen, T
Reports
Metrics
Events
AI Stock Synopses